Agree totally with 1801 when consider the following from the announcement April 2022
28 April 2022
FDA grants BTX 1801 new Qualified Infectious Disease ProductDesignation StatusKey highlights
• The US FDA has granted Botanix new Qualified Infectious Disease Product (QIDP) designation for its investigational antibacterial product, BTX 1801
• New QIDP status applies to the use of BTX 1801 to potentially “reduce the risk of Staph. aureus bloodstream infections in colonized patients dependent on central venous catheters-forhemodialysis”
• QIDP status entitles BTX 1801 to receive an additional 5 years of valuable FDA exclusivity in addition to exclusivity associated with drug approval, and provides eligibility for ‘fast-track status’ and ‘priority FDA review’
• With the recent completion of additional animal studies, the Phase 2 clinical study for BTX 1801remains on track to initiate in 2Q 2022Philadelphia PA and Phoenix AZ, 28
Cheers
- Forums
- ASX - By Stock
- BOT
- BOT - Anything but charting
BOT - Anything but charting, page-7791
-
-
- There are more pages in this discussion • 1,481 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $669.7M |
Open | High | Low | Value | Volume |
37.5¢ | 37.5¢ | 35.0¢ | $2.935M | 8.056M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 236704 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 353190 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 198353 | 0.370 |
17 | 234895 | 0.365 |
13 | 401661 | 0.360 |
11 | 926849 | 0.355 |
13 | 842903 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 376011 | 6 |
0.380 | 516215 | 16 |
0.385 | 207424 | 8 |
0.390 | 723886 | 12 |
0.395 | 338769 | 11 |
Last trade - 14.52pm 15/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online